Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Regulatory Issues of Platform Trials: Learnings from EU-PEARL.

Mesenbrink, Peter and Hernandez Penna Straube, Sabina (2024) Regulatory Issues of Platform Trials: Learnings from EU-PEARL. Clinical pharmacology and therapeutics. ISSN 1532-6535

Official URL: doi:10.1002/cpt.3244

Abstract

Although platform trials have many benefits, the complexity of these designs may result not only in increased methodological but also regulatory and ethical challenges. These aspects were addressed as part of the IMI project EU Patient-Centric Clinical Trial Platforms (EU-PEARL). We reviewed the available guidelines on platform trials in the European Union and the United States. This is supported and complemented by feedback received from regulatory interactions with the European Medicines Agency and the US Food and Drug Administration. Throughout the project we collected the needs of all relevant stakeholders including ethics committees, regulators, and health technology assessment bodies through active dialog and dedicated stakeholder workshops. Furthermore, we focused on methodological aspects and where applicable identified the corresponding guidance. Learnings from the guideline review, regulatory interactions, and workshops are provided. Based on these, a master protocol template was developed. Issues that still need harmonization or clarification in guidelines or where further methodological research is needed are also presented. These include questions around clinical trial submissions in Europe, the need for multiplicity control across the whole master protocol, the use of non-concurrent controls, and the impact of different randomization schemes. Master protocols are an efficient and patient-centered clinical trial design that can expedite drug development. However, they can also introduce additional operational and regulatory complexities. It is important to understand the different requirements of stakeholders upfront and address them in the trial. While relevant guidance is increasing, early dialog with relevant stakeholders can help to further support such designs.

Item Type: Article
Date Deposited: 23 Apr 2024 00:46
Last Modified: 23 Apr 2024 00:46
URI: https://oak.novartis.com/id/eprint/51708

Search